Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors. 2018

Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai 201418, China. Electronic address: chengliping@sit.edu.cn.

Neuraminidase (NA) is an important antiviral drug target. Zanamivir is one of the most potent NA inhibitors. In this paper, a series of zanamivir derivatives as potential NA inhibitors were studied by combination of molecular modeling techniques including 3D-QSAR, molecular docking, and molecular dynamics (MD) simulation. The results show that the best CoMFA (comparative molecular field analysis) model has q2 = 0.728 and r2 = 0.988, and the best CoMSIA (comparative molecular similarity indices analysis) model has q2 = 0.750 and r2 = 0.981, respectively. The built 3D-QSAR models show significant statistical quality and excellent predictive ability. Seven new NA inhibitors were designed and predicted. 20 ns of MD simulations were carried out and their binding free energies were calculated. Two designed compounds were selected to be synthesized and biologically evaluated by NA inhibition and virus inhibition assays. One compound (IC50 = 0.670 µM, SI > 149) exhibits excellent antiviral activity against A/WSN/33 H1N1, which is superior to the reference drug zanamivir (IC50 = 0.873 µM, SI > 115). The theoretical and experimental results may provide reference for development of new anti-influenza drugs.

UI MeSH Term Description Entries
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D053118 Influenza A Virus, H1N1 Subtype A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918 and 2009 H1N1 pandemic. H1N1 Influenza Virus,H1N1 Virus,H1N1 subtype,H1N1v Viruses,Influenza A (H1N1)pdm09,Influenza A (H1N1)pdm09 Virus,Influenza A H1N1, Variant Virus,Swine-Origin Influenza A H1N1 Virus,H1N1 Influenza Viruses,H1N1 Viruses,H1N1 subtypes,H1N1v Virus,Influenza Virus, H1N1,Swine Origin Influenza A H1N1 Virus,Virus, H1N1,Virus, H1N1 Influenza,Virus, H1N1v,subtype, H1N1
D053243 Zanamivir A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE. 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminic Acid,2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminic Acid,4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminic Acid,4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid,4-Guanidino-Neu5Ac2en,5-Acetylamino-2,6-Anhydro-4-Guanidino-3,4,5-Trideoxy-D-Galacto-Non-Enoic Acid,GG 167,GG-167,GG167,Relenza,4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid,4 Guanidino Neu5Ac2en,Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
September 2020, ACS medicinal chemistry letters,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
April 2021, Bioorganic & medicinal chemistry letters,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
March 2022, Bioorganic & medicinal chemistry,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
April 2022, Bioorganic & medicinal chemistry letters,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
September 2021, Bioorganic chemistry,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
December 2009, Bioorganic & medicinal chemistry letters,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
November 2019, Journal of Asian natural products research,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
April 2019, European journal of medicinal chemistry,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
November 2019, European journal of medicinal chemistry,
Li Ping Cheng, and Tian Chi Wang, and Rao Yu, and Meng Li, and Jin Wen Huang
August 2011, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!